{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:58:27Z","timestamp":1792760307086,"version":"4.5.0"},"reference-count":160,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T00:00:00Z","timestamp":1720224000000},"content-version":"am","delay-in-days":371,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jaci-inpractice.org","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jaip.2023.03.015","type":"journal-article","created":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T14:58:26Z","timestamp":1679410706000},"page":"2032-2042","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Research Advances in Mast Cell Biology and Their Translation Into Novel Therapies for Anaphylaxis"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6655-3279","authenticated-orcid":false,"given":"Melanie C.","family":"Dispenza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean D.","family":"Metcalfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Olivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2023.03.015_bib1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13601-017-0182-7","article-title":"How to manage anaphylaxis in primary care","volume":"7","author":"Alvarez-Perea","year":"2017","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaip.2023.03.015_bib2","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/ACI.0b013e3283036a90","article-title":"Understanding the mechanisms of anaphylaxis","volume":"8","author":"Peavy","year":"2008","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib3","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jaci.2020.01.017","article-title":"Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis","volume":"145","author":"Shaker","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib4","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jaci.2017.06.003","article-title":"The pathophysiology of anaphylaxis","volume":"140","author":"Reber","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib5","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jaci.2021.02.012","article-title":"Non-IgE-mediated anaphylaxis","volume":"147","author":"Cianferoni","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib6","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/j.jaci.2016.02.015","article-title":"Human IgE-independent systemic anaphylaxis","volume":"137","author":"Finkelman","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib7","doi-asserted-by":"crossref","first-page":"73","DOI":"10.18176\/jiaci.0046","article-title":"Mechanisms of anaphylaxis beyond IgE","volume":"26","author":"Munoz-Cano","year":"2016","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"issue":"suppl 2","key":"10.1016\/j.jaip.2023.03.015_bib8","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13223-018-0283-4","volume":"14","author":"Fischer","year":"2018","journal-title":"Anaphylaxis. Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib9","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/ACI.0b013e32833bc670","article-title":"Epinephrine and its use in anaphylaxis: current issues","volume":"10","author":"Simons","year":"2010","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib10","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1385\/CRIAI:31:2:131","article-title":"Regulation of mast cells by beta-agonists","volume":"31","author":"Peachell","year":"2006","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.614402","article-title":"Targeting the Fc\u03b5RI pathway as a potential strategy to prevent food-induced anaphylaxis","volume":"11","author":"Dispenza","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib12","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.iac.2020.06.007","article-title":"Targeting mast cells with biologics","volume":"40","author":"Lyons","year":"2020","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2023.03.015_bib13","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0065-2776(08)00403-3","article-title":"New insights on mast cell activation via the high affinity receptor for IgE","volume":"98","author":"Rivera","year":"2008","journal-title":"Adv Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib14","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jid.2020.09.017","article-title":"MRGPRX2 is the codeine receptor of human skin mast cells: desensitization through \u03b2-arrestin and lack of correlation with the Fc\u03b5RI pathway","volume":"141","author":"Babina","year":"2021","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaip.2023.03.015_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-29965-8","article-title":"MRGPRX2-mediated mast cell response to drugs used in perioperative procedures and anaesthesia","volume":"8","author":"Navines-Ferrer","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaip.2023.03.015_bib16","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jaci.2016.04.051","article-title":"Roles of Mas-related G protein-coupled receptor X2 on mast cell-mediated host defense, pseudoallergic drug reactions, and chronic inflammatory diseases","volume":"138","author":"Subramanian","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib17","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1002\/eji.201746951","article-title":"Typical antimicrobials induce mast cell degranulation and anaphylactoid reactions via MRGPRX2 and its murine homologue MRGPRB2","volume":"47","author":"Zhang","year":"2017","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.676354","article-title":"MRGPRX2 and adverse drug reactions","volume":"12","author":"McNeil","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1033794","article-title":"Inhibition of MRGPRX2 but not Fc\u03b5RI or MrgprB2-mediated mast cell degranulation by a small molecule inverse receptor agonist","volume":"13","author":"Bawazir","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib20","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/JLB.2AB1018-405R","article-title":"Novel MRGPRX2 antagonists inhibit IgE-independent activation of human umbilical cord blood-derived mast cells","volume":"106","author":"Ogasawara","year":"2019","journal-title":"J\u00a0Leukoc Biol"},{"key":"10.1016\/j.jaip.2023.03.015_bib21","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/imr.12340","article-title":"Structure and dynamics of IgE-receptor interactions: Fc\u03b5RI and CD23\/Fc\u03b5RII","volume":"268","author":"Sutton","year":"2015","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jaip.2023.03.015_bib22","doi-asserted-by":"crossref","first-page":"22427","DOI":"10.1016\/S0021-9258(17)31807-0","article-title":"Src homology 2 domains of Syk and Lyn bind to tyrosine-phosphorylated subunits of the high affinity IgE receptor","volume":"269","author":"Kihara","year":"1994","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jaip.2023.03.015_bib23","doi-asserted-by":"crossref","first-page":"27962","DOI":"10.1074\/jbc.271.44.27962","article-title":"Downstream signaling molecules bind to different phosphorylated immunoreceptor tyrosine-based activation motif (ITAM) peptides of the high affinity IgE receptor","volume":"271","author":"Kimura","year":"1996","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jaip.2023.03.015_bib24","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0165-2478(96)02599-0","article-title":"IgE antibody up-regulates high affinity IgE binding on murine bone marrow-derived mast cells","volume":"52","author":"Hsu","year":"1996","journal-title":"Immunol Lett"},{"key":"10.1016\/j.jaip.2023.03.015_bib25","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.4049\/jimmunol.158.6.2517","article-title":"IgE regulates mouse basophil Fc epsilon RI expression in\u00a0vivo","volume":"158","author":"Lantz","year":"1997","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib26","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.4049\/jimmunol.158.3.1438","article-title":"Down-regulation of Fc(epsilon)RI expression on human basophils during in\u00a0vivo treatment of atopic patients with anti-IgE antibody","volume":"158","author":"MacGlashan","year":"1997","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib27","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000237504","article-title":"Serum IgE level drives basophil and mast cell IgE receptor display","volume":"113","author":"MacGlashan","year":"1997","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib28","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1056\/NEJMoa022613","article-title":"Effect of anti-IgE therapy in patients with peanut allergy","volume":"348","author":"Leung","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2023.03.015_bib29","doi-asserted-by":"crossref","first-page":"10474","DOI":"10.1021\/bi00033a020","article-title":"Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE","volume":"34","author":"Liu","year":"1995","journal-title":"Biochemistry"},{"key":"10.1016\/j.jaip.2023.03.015_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11610","article-title":"Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange","volume":"7","author":"Pennington","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaip.2023.03.015_bib31","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jaci.2004.06.032","article-title":"Omalizumab-induced reductions in mast cell Fcepsilon RI expression and function","volume":"114","author":"Beck","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib32","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.jaci.2004.07.064","article-title":"Loss of receptors and IgE in\u00a0vivo during treatment with anti-IgE antibody","volume":"114","author":"MacGlashan","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib33","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/j.jaci.2011.04.009","article-title":"Rapid oral desensitization in combination with omalizumab therapy in patients with cow's milk allergy","volume":"127","author":"Nadeau","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib34","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jaci.2013.09.046","article-title":"A\u00a0pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients","volume":"132","author":"Schneider","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib35","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.jaci.2015.10.005","article-title":"A\u00a0randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy","volume":"137","author":"Wood","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib36","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S2468-1253(17)30392-8","article-title":"Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial","volume":"3","author":"Andorf","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jaip.2023.03.015_bib37","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jaci.2012.05.039","article-title":"Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy","volume":"130","author":"Savage","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib38","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.jaip.2019.01.023","article-title":"Impact of omalizumab on food allergy in patients treated for asthma: a real-life study","volume":"7","author":"Fiocchi","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2023.03.015_bib39","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jaci.2011.01.051","article-title":"A\u00a0phase II, randomized, double-blind, parallel-group, placebo-controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy","volume":"127","author":"Sampson","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib40","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/cea.13897","article-title":"The use of biologics in food allergy","volume":"51","author":"Fiocchi","year":"2021","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2023.03.015_bib41","doi-asserted-by":"crossref","first-page":"243ra85","DOI":"10.1126\/scitranslmed.3008961","article-title":"Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production","volume":"6","author":"Gauvreau","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaip.2023.03.015_bib42","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12931-016-0347-2","article-title":"A\u00a0randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma","volume":"17","author":"Harris","year":"2016","journal-title":"Respir Res"},{"key":"10.1016\/j.jaip.2023.03.015_bib43","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1016\/j.jaci.2016.06.023","article-title":"A\u00a0randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria","volume":"138","author":"Harris","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib44","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/cmi.2015.19","article-title":"Development of an antibody that neutralizes soluble IgE and eliminates IgE expressing B cells","volume":"13","author":"Nyborg","year":"2016","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib45","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s12325-016-0287-8","article-title":"Pharmacokinetics, pharmacodynamics, and safety of MEDI4212, an anti-IgE monoclonal antibody, in subjects with atopy: a phase I study","volume":"33","author":"Sheldon","year":"2016","journal-title":"Adv Ther"},{"key":"10.1016\/j.jaip.2023.03.015_bib46","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.jaci.2011.11.029","article-title":"Reduction of total IgE by targeted coengagement of IgE B-cell receptor and Fc\u03b3RIIb with Fc-engineered antibody","volume":"129","author":"Chu","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib47","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41467-019-13815-w","article-title":"The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab","volume":"11","author":"Gasser","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaip.2023.03.015_bib48","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/cea.12400","article-title":"Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects","volume":"44","author":"Arm","year":"2014","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2023.03.015_bib49","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1111\/all.14308","article-title":"Past, present, and future of anti-IgE biologics","volume":"75","author":"Guntern","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2023.03.015_bib50","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1016\/j.jaip.2022.09.020","article-title":"A\u00a0review of adverse reactions to biologics used in allergy-immunology practice","volume":"10","author":"Chow","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2023.03.015_bib51","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1900408","article-title":"Ligelizumab for chronic spontaneous urticaria","volume":"381","author":"Maurer","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2023.03.015_bib52","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1111\/all.15175","article-title":"Sustained safety and efficacy of ligelizumab in patients with chronic spontaneous urticaria: a one-year extension study","volume":"77","author":"Maurer","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2023.03.015_bib53","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jaci.2016.02.027","article-title":"Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses","volume":"138","author":"Gauvreau","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib54","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12038","article-title":"Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab","volume":"11","author":"Li","year":"2021","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaip.2023.03.015_bib55","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jaci.2016.03.030","article-title":"Anaphylactic reactions associated with omalizumab administration: analysis of a case-control study","volume":"138","author":"Lieberman","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib56","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3389\/fimmu.2014.00061","article-title":"Helminth allergens, parasite-specific IgE, and Its protective role in human immunity","volume":"5","author":"Fitzsimmons","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib57","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2222.2007.02650.x","article-title":"Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection","volume":"37","author":"Cruz","year":"2007","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2023.03.015_bib58","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.4049\/jimmunol.1601026","article-title":"Cutting edge: IgE plays an active role in tumor immunosurveillance in mice","volume":"197","author":"Nigro","year":"2016","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib59","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.jaci.2012.01.033","article-title":"Omalizumab and the risk of malignancy: results from a pooled analysis","volume":"129","author":"Busse","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib60","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/j.jaci.2014.02.005","article-title":"Accelerated dissociation of IgE-Fc\u03b5RI complexes by disruptive inhibitors actively desensitizes allergic effector cells","volume":"133","author":"Eggel","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib61","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jaci.2019.11.002","article-title":"Disruptive anti-IgE inhibitors prevent mast cell-dependent early airway response in viable atopic lung tissue","volume":"145","author":"Delgado","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib62","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.jaci.2021.03.050","article-title":"Structure-guided design of ultrapotent disruptive IgE inhibitors to rapidly terminate acute allergic reactions","volume":"148","author":"Pennington","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib63","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.jaci.2020.11.005","article-title":"A\u00a0randomized double-blind, placebo-controlled study of omalizumab for idiopathic anaphylaxis","volume":"147","author":"Carter","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib64","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.jaci.2017.06.032","article-title":"Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence","volume":"141","author":"Maurer","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib65","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ejim.2019.11.010","article-title":"Timing of response and long term efficacy of omalizumab in non-clonal mast cell activation syndrome: a case series","volume":"71","author":"Caminati","year":"2020","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jaip.2023.03.015_bib66","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1159\/000504842","article-title":"Efficacy of omalizumab in mastocytosis: allusive indication obtained from a prospective, double-blind, multicenter study (XOLMA Study)","volume":"236","author":"Distler","year":"2020","journal-title":"Dermatology"},{"key":"10.1016\/j.jaip.2023.03.015_bib67","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.intimp.2010.12.018","article-title":"Inhibition of IgE-mediated secretion from human basophils with a highly selective Bruton's tyrosine kinase, BTK, inhibitor","volume":"11","author":"MacGlashan","year":"2011","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jaip.2023.03.015_bib68","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1111\/all.13166","article-title":"BTK inhibition is a potent approach to block IgE-mediated histamine release in human basophils","volume":"72","author":"Smiljkovic","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2023.03.015_bib69","doi-asserted-by":"crossref","first-page":"4759","DOI":"10.1172\/JCI138448","article-title":"Bruton's tyrosine kinase inhibition effectively protects against human IgE-mediated anaphylaxis","volume":"130","author":"Dispenza","year":"2020","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jaip.2023.03.015_bib70","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.jaci.2017.03.013","article-title":"Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity","volume":"140","author":"Regan","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib71","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaip.2023.03.015_bib72","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1016\/j.jaci.2017.12.987","article-title":"Short-term ibrutinib therapy suppresses skin test responses and eliminates IgE-mediated basophil activation in adults with peanut or tree nut allergy","volume":"141","author":"Dispenza","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib73","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jaip.2022.10.017","article-title":"Pretreatment with ibrutinib facilitates rapid drug desensitization in a difficult case of brentuximab vedotin-induced anaphylaxis","volume":"11","author":"Rodsaward","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2023.03.015_bib74","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1038\/s41591-021-01537-w","article-title":"Fenebrutinib in H(1) antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial","volume":"27","author":"Metz","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jaip.2023.03.015_bib75","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.jaci.2022.08.027","article-title":"Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria","volume":"150","author":"Maurer","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib76","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.jaci.2008.04.019","article-title":"Inducing an anergic state in mast cells and basophils without secretion","volume":"121","author":"MacGlashan","year":"2008","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib77","doi-asserted-by":"crossref","first-page":"100","DOI":"10.4193\/Rhino09.147","article-title":"Syk-kinase inhibition prevents mast cell activation in nasal polyps","volume":"49","author":"Patou","year":"2011","journal-title":"Rhinology"},{"key":"10.1016\/j.jaip.2023.03.015_bib78","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1124\/jpet.106.109058","article-title":"R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation","volume":"319","author":"Braselmann","year":"2006","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.jaip.2023.03.015_bib79","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.immuni.2014.05.017","article-title":"Immunoglobulin E signal inhibition during allergen ingestion leads to reversal of established food allergy and induction of regulatory T cells","volume":"41","author":"Burton","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.jaip.2023.03.015_bib80","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.taap.2017.07.015","article-title":"Suppression of IgE-mediated mast cell activation and mouse anaphylaxis via inhibition of Syk activation by 8-formyl-7-hydroxy-4-methylcoumarin, 4mu8C","volume":"332","author":"Nam","year":"2017","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.jaip.2023.03.015_bib81","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/all.12786","article-title":"NecroX-5 suppresses IgE\/Ag-stimulated anaphylaxis and mast cell activation by regulating the SHP-1-Syk signaling module","volume":"71","author":"Li","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2023.03.015_bib82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2017.02.048","article-title":"JTE-852, a novel spleen tyrosine kinase inhibitor, blocks mediator secretion from mast cells with immunoglobulin E crosslinking","volume":"801","author":"Kato","year":"2017","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jaip.2023.03.015_bib83","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1111\/bcp.14923","article-title":"Effects of a topical treatment with spleen tyrosine kinase inhibitor in healthy subjects and patients with cold urticaria or chronic spontaneous urticaria: Results of a phase 1a\/b randomised double-blind placebo-controlled study","volume":"87","author":"Dickson","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jaip.2023.03.015_bib84","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jaci.2005.01.040","article-title":"An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment","volume":"115","author":"Meltzer","year":"2005","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib85","doi-asserted-by":"crossref","first-page":"208","DOI":"10.2500\/aap.2006.27.2861","article-title":"Mast cell inhibitor R112 is well tolerated and affects prostaglandin D2 but not other mediators, symptoms, or nasal volumes in a nasal challenge model of allergic rhinitis","volume":"27","author":"Guyer","year":"2006","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaip.2023.03.015_bib86","series-title":"Down-regulation of mast cell responses through ITIM containing inhibitory receptors","author":"Karra","year":"2011"},{"key":"10.1016\/j.jaip.2023.03.015_bib87","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/JLB.2MR0120-352RR","article-title":"Eosinophil and mast cell Siglecs: from biology to drug target","volume":"108","author":"O'Sullivan","year":"2020","journal-title":"J\u00a0Leukoc Biol"},{"key":"10.1016\/j.jaip.2023.03.015_bib88","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.immuni.2020.01.012","article-title":"Human mast cell proteome reveals unique lineage, putative functions, and structural basis for cell ablation","volume":"52","author":"Plum","year":"2020","journal-title":"Immunity"},{"issue":"6 part 1","key":"10.1016\/j.jaip.2023.03.015_bib89","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1067\/mai.2000.107127","article-title":"Identification of SAF-2, a novel siglec expressed on eosinophils, mast cells, and basophils","volume":"105","author":"Kikly","year":"2000","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib90","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1074\/jbc.275.2.861","article-title":"Siglec-8. A novel eosinophil-specific member of the immunoglobulin superfamily","volume":"275","author":"Floyd","year":"2000","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jaip.2023.03.015_bib91","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jaci.2007.10.004","article-title":"Inhibition of Fc\u03b5RI-dependent mediator release and calcium flux from human mast cells by sialic acid-binding immunoglobulin-like lectin 8 engagement","volume":"121","author":"Yokoi","year":"2008","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib92","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.3390\/cells11071138","article-title":"Functional and phenotypic characterization of Siglec-6 on human mast cells","volume":"11","author":"Robida","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.jaip.2023.03.015_bib93","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.3389\/fimmu.2018.02138","article-title":"Functional inhibitory Siglec-6 is upregulated in human colorectal cancer-associated mast cells","volume":"9","author":"Yu","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib94","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jaci.2014.03.031","article-title":"Siglec-7 is an inhibitory receptor on human mast cells and basophils","volume":"134","author":"Mizrahi","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib95","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1172\/JCI125456","article-title":"CD33 recruitment inhibits IgE-mediated anaphylaxis and desensitizes mast cells to allergen","volume":"129","author":"Duan","year":"2019","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jaip.2023.03.015_bib96","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1056\/NEJMoa2012047","article-title":"Anti-siglec-8 antibody for eosinophilic gastritis and duodenitis","volume":"383","author":"Dellon","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2023.03.015_bib97","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jaci.2022.03.021","article-title":"Lirentelimab for severe and chronic forms of allergic conjunctivitis","volume":"150","author":"Anesi","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib98","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.jaci.2021.12.772","article-title":"An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria","volume":"149","author":"Altrichter","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib99","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000501637","article-title":"AK002, a humanized sialic acid-binding immunoglobulin-like lectin-8 antibody that induces antibody-dependent cell-mediated cytotoxicity against human eosinophils and inhibits mast cell-mediated anaphylaxis in mice","volume":"180","author":"Youngblood","year":"2019","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib100","series-title":"Safety and efficacy data of AK002, an anti-Siglec-8 monoclonal antibody, in patients with indolent systemic mastocytosis (ISM): results from a first-in-human, open-label phase 1 study","year":"2019"},{"key":"10.1016\/j.jaip.2023.03.015_bib101","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1038\/s42003-022-04207-w","article-title":"Discovery of an agonistic Siglec-6 antibody that inhibits and reduces human mast cells","volume":"5","author":"Schanin","year":"2022","journal-title":"Commun Biol"},{"key":"10.1016\/j.jaip.2023.03.015_bib102","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jaci.2022.07.018","article-title":"Expression and regulation of Siglec-6 (CD327) on human mast cells and basophils","volume":"151","author":"Smiljkovic","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib103","series-title":"Targeting the inhibitory receptor Siglec-8 on mast cells represents an attractive approach to reduce MRGPRX2-mediated mast cell activation","year":"2022"},{"key":"10.1016\/j.jaip.2023.03.015_bib104","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41385-020-00336-9","article-title":"A\u00a0monoclonal antibody to Siglec-8 suppresses non-allergic airway inflammation and inhibits IgE-independent mast cell activation","volume":"14","author":"Schanin","year":"2021","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib105","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.650331","article-title":"Mast cell and eosinophil activation are associated with COVID-19 and TLR-mediated viral inflammation: implications for an anti-Siglec-8 antibody","volume":"12","author":"Gebremeskel","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib106","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s12016-018-8678-z","article-title":"The use of biomarkers to predict aero-allergen and food immunotherapy responses","volume":"55","author":"Sindher","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib107","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.972103","article-title":"Biomarkers and mechanisms of tolerance induction in food allergic patients drive new therapeutic approaches","volume":"13","author":"Baloh","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib108","article-title":"High-resolution epitope mapping by AllerScan reveals relationships between IgE and IgG repertoires during peanut oral immunotherapy","volume":"2","author":"Chen","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.jaip.2023.03.015_bib109","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1172\/JCI117701","article-title":"Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors","volume":"95","author":"Daeron","year":"1995","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jaip.2023.03.015_bib110","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/cea.12155","article-title":"Regulation of IgE-mediated signalling in human basophils by CD32b and its role in Syk down-regulation: basic mechanisms in allergic disease","volume":"44","author":"Macglashan","year":"2014","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2023.03.015_bib111","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.jaci.2014.05.042","article-title":"Oral immunotherapy induces IgG antibodies that act through Fc\u03b3RIIb to suppress IgE-mediated hypersensitivity","volume":"134","author":"Burton","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib112","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.jaci.2015.10.043","article-title":"Parameters determining the efficacy of CD32 to inhibit activation of Fc\u03b5RI in human basophils","volume":"137","author":"MacGlashan","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib113","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.603050","article-title":"IgE and IgG antibodies as regulators of mast cell and basophil functions in food allergy","volume":"11","author":"Kanagaratham","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib114","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1172\/JCI25575","article-title":"IgG-blocking antibodies inhibit IgE-mediated anaphylaxis in\u00a0vivo through both antigen interception and Fc gamma RIIb cross-linking","volume":"116","author":"Strait","year":"2006","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jaip.2023.03.015_bib115","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1038\/s41467-018-03636-8","article-title":"Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement","volume":"9","author":"Orengo","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaip.2023.03.015_bib116","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jaci.2021.05.038","article-title":"Targeting immunodominant Bet v 1 epitopes with monoclonal antibodies prevents the birch allergic response","volume":"149","author":"Atanasio","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib117","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jaci.2021.05.039","article-title":"Novel antibody cocktail targeting Bet v 1 rapidly and sustainably treats birch allergy symptoms in a phase 1 study","volume":"149","author":"Gevaert","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib118","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.jaci.2022.06.025","article-title":"REGN1908\/1909 prevented cat allergen-induced early asthmatic responses in an environmental exposure unit","volume":"150","author":"de Blay","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib119","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/j.1398-9995.2004.00332.x","article-title":"A\u00a0bispecific antibody against human IgE and human Fc\u03b3RII that inhibits antigen-induced histamine release by human mast cells and basophils","volume":"59","author":"Tam","year":"2004","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2023.03.015_bib120","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nm0502-518","article-title":"A\u00a0novel human immunoglobulin Fc gamma Fc epsilon bifunctional fusion protein inhibits Fc epsilon RI-mediated degranulation","volume":"8","author":"Zhu","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.jaip.2023.03.015_bib121","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jaci.2007.04.019","article-title":"Modifications to an Fcgamma-Fcvarepsilon fusion protein alter its effectiveness in the inhibition of FcvarepsilonRI-mediated functions","volume":"120","author":"Allen","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib122","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.imlet.2012.01.008","article-title":"Suppression of mast cell degranulation through a dual-targeting tandem IgE-IgG Fc domain biologic engineered to bind with high affinity to Fc\u03b3RIIb","volume":"143","author":"Cemerski","year":"2012","journal-title":"Immunol Lett"},{"key":"10.1016\/j.jaip.2023.03.015_bib123","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jaci.2012.10.018","article-title":"Blockade of peanut allergy with a novel Ara h 2-Fc\u03b3 fusion protein in mice","volume":"131","author":"Liu","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib124","doi-asserted-by":"crossref","first-page":"694","DOI":"10.4049\/jimmunol.177.1.694","article-title":"Fc gamma RIIa, not Fc gamma RIIb, is constitutively and functionally expressed on skin-derived human mast cells","volume":"177","author":"Zhao","year":"2006","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib125","doi-asserted-by":"crossref","first-page":"35139","DOI":"10.1074\/jbc.M404318200","article-title":"Co-aggregation of FcgammaRII with FcepsilonRI on human mast cells inhibits antigen-induced secretion and involves SHIP-Grb2-Dok complexes","volume":"279","author":"Kepley","year":"2004","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jaip.2023.03.015_bib126","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1023\/A:1009680500988","article-title":"Regulation of apoptosis in mast cells","volume":"5","author":"Piliponsky","year":"2000","journal-title":"Apoptosis"},{"key":"10.1016\/j.jaip.2023.03.015_bib127","doi-asserted-by":"crossref","first-page":"868","DOI":"10.3389\/fimmu.2018.00868","article-title":"Controlling mast cell activation and homeostasis: work influenced by Bill Paul that continues today","volume":"9","author":"Caslin","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib128","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3389\/fimmu.2019.00821","article-title":"Mast cells and their progenitors in allergic asthma","volume":"10","author":"Mendez-Enriquez","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib129","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1182\/blood-2005-12-012781","article-title":"Alpha-4 integrins and VCAM-1, but not MAdCAM-1, are essential for recruitment of mast cell progenitors to the inflamed lung","volume":"108","author":"Abonia","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2023.03.015_bib130","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200321","article-title":"Lineage-specific regulation of inducible and constitutive mast cells in allergic airway inflammation","volume":"218","author":"Derakhshan","year":"2021","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jaip.2023.03.015_bib131","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jaci.2015.01.021","article-title":"TH9 cells are required for tissue mast cell accumulation during allergic inflammation","volume":"136","author":"Sehra","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib132","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1385\/IR:34:2:97","article-title":"Development, migration, and survival of mast cells","volume":"34","author":"Okayama","year":"2006","journal-title":"Immunol Res"},{"key":"10.1016\/j.jaip.2023.03.015_bib133","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s12026-008-8046-9","article-title":"Amplification mechanisms for the enhancement of antigen-mediated mast cell activation","volume":"43","author":"Gilfillan","year":"2009","journal-title":"Immunol Res"},{"key":"10.1016\/j.jaip.2023.03.015_bib134","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1152\/physrev.00046.2011","article-title":"Stem cell factor receptor\/c-Kit: from basic science to clinical implications","volume":"92","author":"Lennartsson","year":"2012","journal-title":"Physiol Rev"},{"key":"10.1016\/j.jaip.2023.03.015_bib135","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1182\/blood-2004-02-0631","article-title":"Kit and FcepsilonRI mediate unique and convergent signals for release of inflammatory mediators from human mast cells","volume":"104","author":"Hundley","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2023.03.015_bib136","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1182\/blood-2003-08-2769","article-title":"NTAL phosphorylation is a pivotal link between the signaling cascades leading to human mast cell degranulation following Kit activation and Fc epsilon RI aggregation","volume":"104","author":"Tkaczyk","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2023.03.015_bib137","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1600-065X.2008.00742.x","article-title":"The tyrosine kinase network regulating mast cell activation","volume":"228","author":"Gilfillan","year":"2009","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jaip.2023.03.015_bib138","doi-asserted-by":"crossref","first-page":"631","DOI":"10.3389\/fimmu.2018.00631","article-title":"Targeting sphingosine kinase isoforms effectively reduces growth and survival of neoplastic mast cells with D816V-KIT","volume":"9","author":"Bandara","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib139","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.841045","article-title":"A\u00a0critical function for the transcription factors GLI1 and GLI2 in the proliferation and survival of human mast cells","volume":"13","author":"Falduto","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib140","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1182\/blood.2020010207","article-title":"The association of Greig syndrome and mastocytosis reveals the involvement of the hedgehog pathway in advanced mastocytosis","volume":"138","author":"Polivka","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2023.03.015_bib141","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/s41591-021-01538-9","article-title":"Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial","volume":"27","author":"DeAngelo","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jaip.2023.03.015_bib142","doi-asserted-by":"crossref","first-page":"5576","DOI":"10.1021\/acs.biochem.8b00727","article-title":"Comparison of the kinase profile of midostaurin (Rydapt) with that of its predominant metabolites and the potential relevance of some newly identified targets to leukemia therapy","volume":"57","author":"Manley","year":"2018","journal-title":"Biochemistry"},{"key":"10.1016\/j.jaip.2023.03.015_bib143","first-page":"991741","article-title":"The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations","author":"Ma","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2023.03.015_bib144","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1038\/s41591-021-01539-8","article-title":"Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial","volume":"27","author":"Gotlib","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jaip.2023.03.015_bib145","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jaci.2020.03.044","article-title":"Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis","volume":"146","author":"Hartmann","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib146","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2023.03.015_bib147","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/leu.2015.242","article-title":"Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth","volume":"30","author":"Peter","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jaip.2023.03.015_bib148","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jaci.2018.06.003","article-title":"Midostaurin in patients with indolent systemic mastocytosis: an open-label phase 2 trial","volume":"142","author":"van Anrooij","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib149","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.18632\/oncotarget.3074","article-title":"Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemia","volume":"6","author":"Cerny-Reiterer","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jaip.2023.03.015_bib150","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/j.1398-9995.2009.02122.x","article-title":"Masitinib, a c-kit\/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics","volume":"64","author":"Humbert","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2023.03.015_bib151","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1056\/NEJMoa1613125","article-title":"KIT inhibition by imatinib in patients with severe refractory asthma","volume":"376","author":"Cahill","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2023.03.015_bib152","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1111\/all.15262","article-title":"Anti-KIT monoclonal antibody CDX-0159 induces profound and durable mast cell suppression in a healthy volunteer study","volume":"77","author":"Alvarado","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2023.03.015_bib153","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.604192","article-title":"Stem cell factor neutralization protects from severe anaphylaxis in a murine model of food allergy","volume":"12","author":"Ptaschinski","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib154","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107718","article-title":"Emerging mechanisms contributing to mast cell-mediated pathophysiology with therapeutic implications","volume":"220","author":"Falduto","year":"2021","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jaip.2023.03.015_bib155","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1056\/NEJMe1702653","article-title":"Mast cells and KIT as potential therapeutic targets in severe asthma","volume":"376","author":"Galli","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2023.03.015_bib156","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1002\/eji.201040559","article-title":"Mast cells in allergy and infection: versatile effector and regulatory cells in innate and adaptive immunity","volume":"40","author":"Galli","year":"2010","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib157","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jaci.2004.04.046","article-title":"The biology of Kit in disease and the application of pharmacogenetics","volume":"114","author":"Akin","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.015_bib158","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.pai.0000173054.83414.22","article-title":"KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation","volume":"13","author":"Miettinen","year":"2005","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.jaip.2023.03.015_bib159","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.iac.2014.01.002","article-title":"Functional deregulation of KIT: link to mast cell proliferative diseases and other neoplasms","volume":"34","author":"Cruse","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2023.03.015_bib160","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.it.2012.09.008","article-title":"New models for analyzing mast cell functions in\u00a0vivo","volume":"33","author":"Reber","year":"2012","journal-title":"Trends Immunol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219823002994?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219823002994?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T11:37:38Z","timestamp":1736854658000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219823002994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":160,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S2213219823002994"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2023.03.015","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Research Advances in Mast Cell Biology and Their Translation Into Novel Therapies for Anaphylaxis","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2023.03.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}